The search for anti-cancer drugs has strong support from the Chinese government which has spurred investors to pour money into the sector. What's hot this year seems to be immuno-oncology and the related field of precision medicine.
Traditional chemotherapy indiscriminately attacks cells, whether they are cancerous or not. But more advanced oncology treatments seek to activate a body's own immune system to destroy cancer cells. This is called immuno-oncology I-O, which is more efficient and has fewer side effects.
It is becoming an investment focus for 2019, according to Kevin Xie, co-founder and head of the healthcare advisory team at China Renaissance.